• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因组不稳定性与亚洲人和欧洲人之间在肝细胞癌中的种族差异有关。

Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma.

机构信息

Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, 138672, Singapore.

School of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore.

出版信息

Theranostics. 2022 Jun 6;12(10):4703-4717. doi: 10.7150/thno.71676. eCollection 2022.

DOI:10.7150/thno.71676
PMID:35832070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9254249/
Abstract

Hepatocellular carcinoma (HCC) is one of the deadliest cancer types with diverse etiological factors across the world. Although large scale genomic studies have been conducted in different countries, integrative analysis of HCC genomes and ethnic comparison across cohorts are lacking. We first integrated genomes of 1,349 HCC patients from five large cohorts across the world and applied multiple statistical methods in identifying driver genes. Subsequently, we systematically compared HCC genomes and transcriptomes between Asians and Europeans using the TCGA cohort. We identified 29 novel candidate driver genes, many of which are infrequent tumor suppressors driving late-stage tumor progression. When we systematically compared ethnic differences in the genomic landscape between Asian and European HCCs using the TCGA cohort (n = 348), we found little differences in driver frequencies. Through multi-modal integrative analysis, we found higher genomic instability in Asians together with a collection of molecular events ranging from tumor mutation burden (TMB), copy number alterations as well as transcriptomic subtypes segregating distinctively between two ethnic backgrounds. Strikingly, we identified an Asian specific transcriptomic subtype with multiple ethnically enriched genomic alterations, in particular chromosome 16 deletion, leading to a clinically aggressive RNA subgroup unique to Asians. Integrating multi-modal information, we found that survival models predict patient prognosis much better in Asians than in Europeans, demonstrating a higher potential for precision medicine applications in Asia. For the first time, we have uncovered an unprecedented amount of genomic differences segregating distinctively across ethnicities in HCC and highlighted the importance of differential disease biology and management in HCC across ethnic backgrounds.

摘要

肝细胞癌(HCC)是全球致死率最高的癌症类型之一,其病因多种多样。尽管在不同国家已经开展了大规模的基因组研究,但 HCC 基因组的综合分析以及队列间的种族比较仍然缺乏。我们首先整合了来自全球五个大型队列的 1349 名 HCC 患者的基因组,并应用多种统计方法鉴定了驱动基因。随后,我们使用 TCGA 队列系统地比较了亚洲人和欧洲人 HCC 的基因组和转录组。我们确定了 29 个新的候选驱动基因,其中许多是罕见的肿瘤抑制基因,驱动晚期肿瘤进展。当我们使用 TCGA 队列(n=348)系统地比较亚洲和欧洲 HCC 之间的种族差异时,我们发现驱动频率差异很小。通过多模态综合分析,我们发现亚洲人的基因组不稳定性更高,同时存在一系列分子事件,包括肿瘤突变负荷(TMB)、拷贝数改变以及转录组亚型,这些事件在两种种族背景下明显不同。引人注目的是,我们鉴定了一个亚洲特有的转录组亚型,该亚型具有多个种族特异性的基因组改变,特别是 16 号染色体缺失,导致亚洲人特有的一种具有侵袭性的 RNA 亚群。整合多模态信息,我们发现生存模型在亚洲人预测患者预后方面比在欧洲人更好,这表明在亚洲,精准医学应用的潜力更高。我们首次揭示了 HCC 中不同种族之间存在前所未有的基因组差异,并强调了在不同种族背景下 HCC 疾病生物学和管理的差异性的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/e0496b367356/thnov12p4703g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/1966d370b1c6/thnov12p4703g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/f3e5842863c6/thnov12p4703g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/5f5f55fca235/thnov12p4703g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/5a72d7b06ab6/thnov12p4703g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/e0496b367356/thnov12p4703g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/1966d370b1c6/thnov12p4703g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/f3e5842863c6/thnov12p4703g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/5f5f55fca235/thnov12p4703g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/5a72d7b06ab6/thnov12p4703g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5685/9254249/e0496b367356/thnov12p4703g005.jpg

相似文献

1
Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma.基因组不稳定性与亚洲人和欧洲人之间在肝细胞癌中的种族差异有关。
Theranostics. 2022 Jun 6;12(10):4703-4717. doi: 10.7150/thno.71676. eCollection 2022.
2
Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma.构建基于基因组不稳定性的 lncRNA 风险评分系统用于预测肝细胞癌的预后。
Aging (Albany NY). 2021 Nov 18;13(22):24621-24639. doi: 10.18632/aging.203698.
3
Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.从 MT1 缺失的肝细胞癌中鉴定潜在的生物标志物。
Pathol Oncol Res. 2021 Apr 1;27:597527. doi: 10.3389/pore.2021.597527. eCollection 2021.
4
Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations.亚裔美国人和欧美人群肝细胞癌体细胞突变图谱的差异。
Oncotarget. 2016 Jun 28;7(26):40491-40499. doi: 10.18632/oncotarget.9636.
5
Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma.七衰老相关基因特征可预测亚洲肝细胞癌患者的总生存期。
World J Gastroenterol. 2019 Apr 14;25(14):1715-1728. doi: 10.3748/wjg.v25.i14.1715.
6
Genetic alterations in hepatocellular carcinoma: An update.肝细胞癌中的基因改变:最新进展
World J Gastroenterol. 2016 Nov 7;22(41):9069-9095. doi: 10.3748/wjg.v22.i41.9069.
7
Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution.多区域全基因组测序分析表现为结节内结节样外观的肝细胞癌揭示了逐步发生的癌症演进过程。
J Pathol. 2020 Dec;252(4):398-410. doi: 10.1002/path.5533. Epub 2020 Sep 29.
8
Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes.基于凋亡相关基因挖掘亚洲肝细胞癌患者的预后标志物。
BMC Cancer. 2021 Feb 18;21(1):175. doi: 10.1186/s12885-021-07886-6.
9
Hepatitis B carriage explains the excess rate of hepatocellular carcinoma for Maori, Pacific Island and Asian people compared to Europeans in New Zealand.乙肝病毒携带率解释了在新西兰,毛利人、太平洋岛民和亚洲人相较于欧洲人肝细胞癌发病率更高的原因。
Int J Epidemiol. 1999 Apr;28(2):204-10. doi: 10.1093/ije/28.2.204.
10
Integrative molecular analysis of metastatic hepatocellular carcinoma.转移性肝细胞癌的综合分子分析。
BMC Med Genomics. 2019 Nov 13;12(1):164. doi: 10.1186/s12920-019-0586-4.

引用本文的文献

1
Characterization of Mutational Signatures in Tumors from a Large Chinese Population.中国大规模人群肿瘤中突变特征的表征
Cancer Res Commun. 2025 Aug 1;5(8):1466-1476. doi: 10.1158/2767-9764.CRC-24-0496.
2
Associations between dynamic-contrast enhanced MRI with histopathological features in atypical HCC using spatial co-registration with biopsy.使用活检的空间共配准技术,研究非典型肝癌动态对比增强磁共振成像与组织病理学特征之间的关联。
Am J Transl Res. 2025 Apr 15;17(4):2967-2975. doi: 10.62347/PJYE7877. eCollection 2025.
3
Hepatic Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor Levels Decline in Hepatitis C but Are Not Associated with Progression of Hepatocellular Carcinoma.

本文引用的文献

1
Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis.按病因分析肝细胞癌的生存率:一项监测、流行病学和最终结果(SEER)-医疗保险数据库分析
Hepatol Commun. 2020 Aug 9;4(10):1541-1551. doi: 10.1002/hep4.1564. eCollection 2020 Oct.
2
The genomic landscape of Mongolian hepatocellular carcinoma.蒙古肝细胞癌的基因组图谱。
Nat Commun. 2020 Sep 1;11(1):4383. doi: 10.1038/s41467-020-18186-1.
3
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.癌症免疫治疗的新时代:靶向髓系来源抑制细胞以克服免疫逃逸。
丙型肝炎患者肝脏骨形态发生蛋白和激活素膜结合抑制剂水平下降,但与肝细胞癌进展无关。
Biomedicines. 2024 Oct 19;12(10):2397. doi: 10.3390/biomedicines12102397.
4
Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses.肝癌中的新型基因改变可区分不同的临床结局和联合免疫治疗反应。
Front Pharmacol. 2024 Jun 14;15:1416295. doi: 10.3389/fphar.2024.1416295. eCollection 2024.
5
Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma.肿瘤系统地理学揭示了肝癌呈块状的空间异质性和进化模式。
Nat Commun. 2024 Apr 12;15(1):3169. doi: 10.1038/s41467-024-47541-9.
6
Characterization of highly active mutational signatures in tumors from a large Chinese population.中国大规模人群肿瘤中高活性突变特征的表征
medRxiv. 2023 Nov 4:2023.11.03.23297964. doi: 10.1101/2023.11.03.23297964.
7
Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.Y90 树脂微球放射栓塞后继以nivolumab 治疗晚期肝细胞癌的多模态分子反应图谱。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007106.
Front Immunol. 2020 Jul 30;11:1680. doi: 10.3389/fimmu.2020.01680. eCollection 2020.
4
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer.癌症遗传祖源的综合分析及其分子相关性
Cancer Cell. 2020 May 11;37(5):639-654.e6. doi: 10.1016/j.ccell.2020.04.012.
5
The repertoire of mutational signatures in human cancer.人类癌症中的突变特征谱。
Nature. 2020 Feb;578(7793):94-101. doi: 10.1038/s41586-020-1943-3. Epub 2020 Feb 5.
6
Genomic landscape of lung adenocarcinoma in East Asians.东亚肺腺癌的基因组景观。
Nat Genet. 2020 Feb;52(2):177-186. doi: 10.1038/s41588-019-0569-6. Epub 2020 Feb 3.
7
Epidemiology and surveillance for hepatocellular carcinoma: New trends.肝癌的流行病学和监测:新趋势。
J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025.
8
Advances in molecular classification and precision oncology in hepatocellular carcinoma.肝细胞癌的分子分类和精准肿瘤学进展。
J Hepatol. 2020 Feb;72(2):215-229. doi: 10.1016/j.jhep.2019.08.017.
9
Intratumoral heterogeneity and clonal evolution in liver cancer.肝癌中的肿瘤内异质性和克隆进化。
Nat Commun. 2020 Jan 15;11(1):291. doi: 10.1038/s41467-019-14050-z.
10
Tumour evolution in hepatocellular carcinoma.肝细胞癌中的肿瘤演进。
Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):139-152. doi: 10.1038/s41575-019-0229-4. Epub 2019 Dec 2.